Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials

Domenic A. Ciraulo, Robert Hitzemann, Eugene Somoza, Clifford M. Knapp, John Rotrosen, Ofra Sarid-Segal, Ann Marie Ciraulo, David J. Greenblatt, C. Nora Chiang

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses of sublingual tablets containing either buprenorphine alone or buprenorphine and naloxone. Subjects were experienced opiate users who received escalating doses (4-24 mg) of buprenorphine either alone or in combination with naloxone. Peak concentration (Cmax) and area under the concentration-time curves (AUCs) increased for both buprenorphine and naloxone with escalating doses. Significant differences were found across the range of doses administered for dose-adjusted Cmax for both tablet formulations and for the dose-adjusted AUCs for the buprenorphine-naloxone tablets. For both formulations, the maximal buprenorphine-induced decreases in respiratory rate and pupil diameter did not vary significantly across doses. Several of the subjective effects of buprenorphine did not increase as the dose of buprenorphine administered was increased. These findings are consistent with the ceiling effect associated with the partial agonist actions of buprenorphine. They also indicate a lack of dose proportionality for buprenorphine sublingual tablets, at least during the times at which levels of this agent are highest.

Original languageEnglish (US)
Pages (from-to)179-192
Number of pages14
JournalJournal of Clinical Pharmacology
Volume46
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Buprenorphine
Tablets
Pharmacokinetics
Opiate Alkaloids
Pupil
Respiratory Rate
Naloxone

Keywords

  • Naloxone
  • Opioid dependence
  • Partial agonist
  • Sublingual

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. / Ciraulo, Domenic A.; Hitzemann, Robert; Somoza, Eugene; Knapp, Clifford M.; Rotrosen, John; Sarid-Segal, Ofra; Ciraulo, Ann Marie; Greenblatt, David J.; Chiang, C. Nora.

In: Journal of Clinical Pharmacology, Vol. 46, No. 2, 02.2006, p. 179-192.

Research output: Contribution to journalArticle

Ciraulo, DA, Hitzemann, R, Somoza, E, Knapp, CM, Rotrosen, J, Sarid-Segal, O, Ciraulo, AM, Greenblatt, DJ & Chiang, CN 2006, 'Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials', Journal of Clinical Pharmacology, vol. 46, no. 2, pp. 179-192. https://doi.org/10.1177/0091270005284192
Ciraulo, Domenic A. ; Hitzemann, Robert ; Somoza, Eugene ; Knapp, Clifford M. ; Rotrosen, John ; Sarid-Segal, Ofra ; Ciraulo, Ann Marie ; Greenblatt, David J. ; Chiang, C. Nora. / Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. In: Journal of Clinical Pharmacology. 2006 ; Vol. 46, No. 2. pp. 179-192.
@article{ca294bd816634fa783a28facc5f95fe6,
title = "Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials",
abstract = "In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses of sublingual tablets containing either buprenorphine alone or buprenorphine and naloxone. Subjects were experienced opiate users who received escalating doses (4-24 mg) of buprenorphine either alone or in combination with naloxone. Peak concentration (Cmax) and area under the concentration-time curves (AUCs) increased for both buprenorphine and naloxone with escalating doses. Significant differences were found across the range of doses administered for dose-adjusted Cmax for both tablet formulations and for the dose-adjusted AUCs for the buprenorphine-naloxone tablets. For both formulations, the maximal buprenorphine-induced decreases in respiratory rate and pupil diameter did not vary significantly across doses. Several of the subjective effects of buprenorphine did not increase as the dose of buprenorphine administered was increased. These findings are consistent with the ceiling effect associated with the partial agonist actions of buprenorphine. They also indicate a lack of dose proportionality for buprenorphine sublingual tablets, at least during the times at which levels of this agent are highest.",
keywords = "Naloxone, Opioid dependence, Partial agonist, Sublingual",
author = "Ciraulo, {Domenic A.} and Robert Hitzemann and Eugene Somoza and Knapp, {Clifford M.} and John Rotrosen and Ofra Sarid-Segal and Ciraulo, {Ann Marie} and Greenblatt, {David J.} and Chiang, {C. Nora}",
year = "2006",
month = "2",
doi = "10.1177/0091270005284192",
language = "English (US)",
volume = "46",
pages = "179--192",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials

AU - Ciraulo, Domenic A.

AU - Hitzemann, Robert

AU - Somoza, Eugene

AU - Knapp, Clifford M.

AU - Rotrosen, John

AU - Sarid-Segal, Ofra

AU - Ciraulo, Ann Marie

AU - Greenblatt, David J.

AU - Chiang, C. Nora

PY - 2006/2

Y1 - 2006/2

N2 - In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses of sublingual tablets containing either buprenorphine alone or buprenorphine and naloxone. Subjects were experienced opiate users who received escalating doses (4-24 mg) of buprenorphine either alone or in combination with naloxone. Peak concentration (Cmax) and area under the concentration-time curves (AUCs) increased for both buprenorphine and naloxone with escalating doses. Significant differences were found across the range of doses administered for dose-adjusted Cmax for both tablet formulations and for the dose-adjusted AUCs for the buprenorphine-naloxone tablets. For both formulations, the maximal buprenorphine-induced decreases in respiratory rate and pupil diameter did not vary significantly across doses. Several of the subjective effects of buprenorphine did not increase as the dose of buprenorphine administered was increased. These findings are consistent with the ceiling effect associated with the partial agonist actions of buprenorphine. They also indicate a lack of dose proportionality for buprenorphine sublingual tablets, at least during the times at which levels of this agent are highest.

AB - In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses of sublingual tablets containing either buprenorphine alone or buprenorphine and naloxone. Subjects were experienced opiate users who received escalating doses (4-24 mg) of buprenorphine either alone or in combination with naloxone. Peak concentration (Cmax) and area under the concentration-time curves (AUCs) increased for both buprenorphine and naloxone with escalating doses. Significant differences were found across the range of doses administered for dose-adjusted Cmax for both tablet formulations and for the dose-adjusted AUCs for the buprenorphine-naloxone tablets. For both formulations, the maximal buprenorphine-induced decreases in respiratory rate and pupil diameter did not vary significantly across doses. Several of the subjective effects of buprenorphine did not increase as the dose of buprenorphine administered was increased. These findings are consistent with the ceiling effect associated with the partial agonist actions of buprenorphine. They also indicate a lack of dose proportionality for buprenorphine sublingual tablets, at least during the times at which levels of this agent are highest.

KW - Naloxone

KW - Opioid dependence

KW - Partial agonist

KW - Sublingual

UR - http://www.scopus.com/inward/record.url?scp=31344467522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344467522&partnerID=8YFLogxK

U2 - 10.1177/0091270005284192

DO - 10.1177/0091270005284192

M3 - Article

C2 - 16432270

AN - SCOPUS:31344467522

VL - 46

SP - 179

EP - 192

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 2

ER -